Objectives: To assess the efficacy and toxicity profile of single agent docetaxel at a higher dose than previously evaluated in patients with androgen-independent prostate cancer (AIPC).
Patients And Methods: Patients with metastatic and progressive AIPC were treated with docetaxel 100 mg/m on day 1 of a 3-week cycle.
Results: Twenty-five patients with overt and rapid symptomatic deterioration from AIPC were entered into this study. Nine men achieved a reduction in PSA of >50% and 4 >80% for an overall PSA response of 52% (95% confidence interval [CI], 31-73%). Sixty percent of men experienced pain relief. Of 16 subjects with measurable disease, 25% achieved partial response (95% CI, 0-48 months), 44% stable disease, and 31% progressed. Median time to progression was 4.5 months (95% CI, 2.9-6.1 month) and median survival was 9.3 months (95% CI, 5.7-12.9 months). Toxicity was significant and included grade 3 or greater neutropenia (76%), dehydration (16%), thrombosis (8%), confusion (4%), and death (4%).
Conclusion: Docetaxel is an active agent against AIPC and should be used judiciously. The side effect profile of the 100 mg/m dose was significant and cannot be recommended for everyday clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.coc.0000221357.12412.b7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Virol J
January 2025
Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518118, China.
Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.
View Article and Find Full Text PDFPurpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease.
Methods: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA) were evaluated during osilodrostat treatment in patients with/without hypertension or diabetes at baseline.
Effect of rapid and slow intravenous injection of sodium penicillin on arterial blood pressure in isoflurane-anesthetized horses during surgery.
Vet Anaesth Analg
January 2025
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada.
Objective: To determine the effects of rapid (1 minute) and slow (10 minutes) intravenous (IV) injection of sodium penicillin on arterial blood pressure in anesthetized horses.
Study Design: Prospective randomized clinical trial.
Animals: A group of 29 client-owned horses of various breeds, 1-20 years old, with body masses of 360-710 kg.
Comparative study on the inactivation and immunogenicity of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different inactivants.
Vaccine
January 2025
Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture and Rural Affairs, Nanjing, China; GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou, China; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China. Electronic address:
The present study aimed to investigate the optimal inactivants and inactivation conditions for preparing inactivated vaccines of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis. Mycoplasma inactivation was performed using formaldehyde, thimerosal, β-propiolactone (BPL), and binary ethylenimine (BEI) and compared. The results showed that M.
View Article and Find Full Text PDFPredictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial.
Gut
January 2025
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
Background: Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!